$76.49
0.41% yesterday
NYSE, Jul 18, 10:10 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$76.49
+2.51 3.39% 1M
+6.71 9.62% 6M
+2.46 3.32% YTD
-9.32 10.86% 1Y
-20.96 21.51% 3Y
+1.85 2.48% 5Y
+50.82 197.99% 10Y
+73.08 2,143.11% 20Y
NYSE, Closing price Fri, Jul 18 2025
+0.31 0.41%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Basic
Market capitalization
$44.7b
Enterprise Value
$41.4b
Net debt
positive
Cash
$3.9b
Shares outstanding
586.2m
Valuation (TTM | estimate)
P/E
10.7 | 29.8
P/S
8.1 | 7.3
EV/Sales
7.5 | 6.8
EV/FCF
66.4
P/B
4.4
Financial Health
Equity Ratio
76.6%
Return on Equity
41.8%
ROCE
13.2%
ROIC
16.3%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$5.5b | $6.1b
EBITDA
$1.7b | $1.8b
EBIT
$1.5b | $1.7b
Net Income
$4.2b | $1.5b
Free Cash Flow
$623.1m
Growth (TTM | estimate)
Revenue
-6.0% | 11.9%
EBITDA
-7.8% | 10.6%
EBIT
-8.8% | 11.6%
Net Income
195.7% | -64.1%
Free Cash Flow
161.7%
Margin (TTM | estimate)
Gross
79.4%
EBITDA
30.5% | 29.7%
EBIT
27.7%
Net
75.5% | 24.6%
Free Cash Flow
11.3%
More
EPS
$7.1
FCF per Share
$1.1
Short interest
1.2%
Employees
16k
Rev per Employee
$340.0k
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

41 Analysts have issued a Edwards Lifesciences forecast:

23x Buy
56%
17x Hold
41%
1x Sell
2%

Analyst Opinions

41 Analysts have issued a Edwards Lifesciences forecast:

Buy
56%
Hold
41%
Sell
2%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5,539 5,539
6% 6%
100%
- Direct Costs 1,142 1,142
15% 15%
21%
4,397 4,397
3% 3%
79%
- Selling and Administrative Expenses 1,830 1,830
0% 0%
33%
- Research and Development Expense 1,052 1,052
2% 2%
19%
1,688 1,688
8% 8%
30%
- Depreciation and Amortization 153 153
3% 3%
3%
EBIT (Operating Income) EBIT 1,535 1,535
9% 9%
28%
Net Profit 4,181 4,181
196% 196%
75%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
about 18 hours ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2025 after the market closes on Thursday July 24, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and arc...
Positive
Seeking Alpha
about one month ago
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&...
Neutral
Investors Business Daily
about 2 months ago
Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today